These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23827980)

  • 1. Time trends and determinants of pharmaceutical expenditure in China (1990-2009).
    Shi L; Yang HY; Cheng G; Meng Q
    Pharmacoeconomics; 2014 Mar; 32(3):257-64. PubMed ID: 23827980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of promoting access to medicines in China - problems and recommendations.
    Sun J; Hu CJ; Stuntz M; Hogerzeil H; Liu Y
    BMC Health Serv Res; 2018 Feb; 18(1):125. PubMed ID: 29458428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.
    He Y; Dou G; Huang Q; Zhang X; Ye Y; Qian M; Ying X
    PLoS One; 2018; 13(1):e0190320. PubMed ID: 29338038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical cost-containment policy: experiences in Shanghai, China.
    Hu S; Chen W; Cheng X; Chen K; Zhou H; Wang L
    Health Policy Plan; 2001 Dec; 16 Suppl 2():4-9. PubMed ID: 11772985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a typical systemic hospital reform on inpatient expenditure for rural population: the Sanming model in China.
    Meng Z; Zhu M; Cai Y; Cao X; Wu H
    BMC Health Serv Res; 2019 Apr; 19(1):231. PubMed ID: 30992013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of China's Public Hospital Reform on Healthcare Expenditures and Utilization: A Case Study in ZJ Province.
    Zhang H; Hu H; Wu C; Yu H; Dong H
    PLoS One; 2015; 10(11):e0143130. PubMed ID: 26588244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Main drivers of health expenditure growth in China: a decomposition analysis.
    Zhai T; Goss J; Li J
    BMC Health Serv Res; 2017 Mar; 17(1):185. PubMed ID: 28274228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug policy in China: pharmaceutical distribution in rural areas.
    Dong H; Bogg L; Rehnberg C; Diwan V
    Soc Sci Med; 1999 Mar; 48(6):777-86. PubMed ID: 10190640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANALYSIS OF TRENDS IN LIFE EXPECTANCIES AND PER CAPITA GROSS DOMESTIC PRODUCT AS WELL AS PHARMACEUTICAL AND NON-PHARMACEUTICAL HEALTHCARE EXPENDITURES.
    Hermanowski T; Bystrov V; Staszewska-Bystrova A; Szafraniec-Buryło SI; Rabczenko D; Kolasa K; Orlewska E
    Acta Pol Pharm; 2015; 72(5):1045-50. PubMed ID: 26665412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China.
    Zhang X; Lai H; Zhang L; He J; Fu B; Jin C
    BMC Health Serv Res; 2020 Nov; 20(1):1058. PubMed ID: 33225941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of health system reform on medical services utilization and expenditures in China in 2004-2015.
    Shu Z; Liu Y; Li M; Li J
    Int Health; 2021 Dec; 13(6):640-647. PubMed ID: 34263307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International health care spending.
    Schieber GJ; Puollier JP
    Health Aff (Millwood); 1986; 5(3):111-22. PubMed ID: 3098657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in health expenditures in China in 2000s: has the health system reform improved affordability.
    Long Q; Xu L; Bekedam H; Tang S
    Int J Equity Health; 2013 Jun; 12():40. PubMed ID: 23764104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.